MX2021000862A - Fucanos altamente purificados para el tratamiento de adherencias fibrosas y métodos para obtenerlos. - Google Patents

Fucanos altamente purificados para el tratamiento de adherencias fibrosas y métodos para obtenerlos.

Info

Publication number
MX2021000862A
MX2021000862A MX2021000862A MX2021000862A MX2021000862A MX 2021000862 A MX2021000862 A MX 2021000862A MX 2021000862 A MX2021000862 A MX 2021000862A MX 2021000862 A MX2021000862 A MX 2021000862A MX 2021000862 A MX2021000862 A MX 2021000862A
Authority
MX
Mexico
Prior art keywords
fucan
fucans
treatment
fibrous adhesions
highly purified
Prior art date
Application number
MX2021000862A
Other languages
English (en)
Inventor
Christopher Michael Kevin Springate
Ian Millet
Sailesh Haresh Daswani
Hesong Sun
Aileen Shao Ting Yang
Hoi Ting Wong
Original Assignee
Arc Medical Devices Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arc Medical Devices Inc filed Critical Arc Medical Devices Inc
Publication of MX2021000862A publication Critical patent/MX2021000862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Artificial Filaments (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicinal Preparation (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

Se proporcionan composiciones, métodos, sistemas, etc., para fucanos modificados y/o purificados y composiciones correspondientes que contienen fucanos que inhiben las adhesiones fibrosas, entre otras ventajas. Los fucanos purificados/modificado s y las composiciones de fucanos tienen un nivel reducido de componentes distintos del fucano o impurezas, tales como las que se encuentran en una composición de fucano inicial. Tal reducción de componentes o impurezas no deseadas incluyen, por ejemplo, componentes no deseados que están unidos al fucano, así como compuestos presentes en la composición que no forman parte del fucano o que no están unidos a éste.
MX2021000862A 2018-07-27 2019-07-24 Fucanos altamente purificados para el tratamiento de adherencias fibrosas y métodos para obtenerlos. MX2021000862A (es)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862711364P 2018-07-27 2018-07-27
US201862711335P 2018-07-27 2018-07-27
US201862711372P 2018-07-27 2018-07-27
US201862713413P 2018-08-01 2018-08-01
US201862713392P 2018-08-01 2018-08-01
US201862713399P 2018-08-01 2018-08-01
US201862722137P 2018-08-23 2018-08-23
US201862722135P 2018-08-23 2018-08-23
US201862755328P 2018-11-02 2018-11-02
US201862755311P 2018-11-02 2018-11-02
US201862755318P 2018-11-02 2018-11-02
US201962793514P 2019-01-17 2019-01-17
US201962793654P 2019-01-17 2019-01-17
US201962861235P 2019-06-13 2019-06-13
US201962861228P 2019-06-13 2019-06-13
US201962861223P 2019-06-13 2019-06-13
PCT/CA2019/051028 WO2020019079A1 (en) 2018-07-27 2019-07-24 Highly purified fucans for the treatment of fibrous adhesions

Publications (1)

Publication Number Publication Date
MX2021000862A true MX2021000862A (es) 2021-07-21

Family

ID=69180222

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2021000863A MX2021000863A (es) 2018-07-27 2019-07-24 Composiciones de fucano altamente purificado y/o modificado para el tratamiento de adhesiones fibrosas.
MX2021000860A MX2021000860A (es) 2018-07-27 2019-07-24 Composiciones de fucano con bajo contenido de endotoxina y métodos para obtenerlas.
MX2021000861A MX2021000861A (es) 2018-07-27 2019-07-24 Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos.
MX2021000864A MX2021000864A (es) 2018-07-27 2019-07-24 Fucanos altos en sulfato para el tratamiento de adhesiones fibrosas.
MX2021000862A MX2021000862A (es) 2018-07-27 2019-07-24 Fucanos altamente purificados para el tratamiento de adherencias fibrosas y métodos para obtenerlos.

Family Applications Before (4)

Application Number Title Priority Date Filing Date
MX2021000863A MX2021000863A (es) 2018-07-27 2019-07-24 Composiciones de fucano altamente purificado y/o modificado para el tratamiento de adhesiones fibrosas.
MX2021000860A MX2021000860A (es) 2018-07-27 2019-07-24 Composiciones de fucano con bajo contenido de endotoxina y métodos para obtenerlas.
MX2021000861A MX2021000861A (es) 2018-07-27 2019-07-24 Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos.
MX2021000864A MX2021000864A (es) 2018-07-27 2019-07-24 Fucanos altos en sulfato para el tratamiento de adhesiones fibrosas.

Country Status (15)

Country Link
US (5) US11419891B2 (es)
EP (5) EP3829600A4 (es)
JP (10) JP7302831B2 (es)
KR (5) KR20210036914A (es)
CN (5) CN112513103B (es)
AU (10) AU2019312088B2 (es)
BR (5) BR112021000631A2 (es)
CA (5) CA3106464A1 (es)
IL (5) IL280168A (es)
MX (5) MX2021000863A (es)
PH (4) PH12021550104A1 (es)
SG (5) SG11202100393TA (es)
TW (4) TW202020035A (es)
WO (5) WO2020019077A1 (es)
ZA (3) ZA202100272B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3829600A4 (en) 2018-07-27 2022-06-15 Arc Medical Devices, Inc. LOW ENDOTOXIN FUCCO COMPOSITIONS, SYSTEMS AND METHODS
WO2023019360A1 (en) * 2021-08-20 2023-02-23 ARC Medical Devices Fucan and modified fucan compositions for the treatment of conditions related to capsular contracture and to inhibiting fibrous growth around or on transplants
TWI829020B (zh) * 2021-10-08 2024-01-11 中華海洋生技股份有限公司 小分子褐藻醣膠用於製備子宮內膜異位症藥物和保健食品之用途
CN114392399B (zh) * 2022-01-26 2022-09-02 青岛琛蓝海洋生物工程有限公司 一种木葡聚糖防粘连膜及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461873A (en) 1982-06-22 1984-07-24 Phillips Petroleum Company Ethylene polymer blends
JPH0491027A (ja) * 1990-08-02 1992-03-24 Taiho Yakuhin Kogyo Kk 抗ヒト免疫不全症ウィルス剤
DE4213963A1 (de) 1992-04-28 1993-11-04 Seitz Filter Werke Verfahren und vorrichtung zur reinigung von abwasser
DE69531044T2 (de) * 1994-03-16 2003-12-04 Univ California Alameda Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung
WO1995035261A1 (fr) 1994-06-22 1995-12-28 Noritake Co., Limited Procede de regeneration des fluides d'usinage et appareil associe
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
IT1288713B1 (it) 1996-12-18 1998-09-23 Crinos Industria Farmaco Fucani a basso peso molecolare aventi attivita' anticoagulante antitrombinica e antitrombotica
JPH10195106A (ja) * 1997-01-13 1998-07-28 Masakuni Tako 養殖イトモズクからの純度の高いフコイダンの製造法
JP4331912B2 (ja) * 2000-04-21 2009-09-16 タカラバイオ株式会社 硫酸化グルクロノフカン
US6868715B1 (en) 2000-09-20 2005-03-22 General Electric Company Method and apparatus for rapid determination of polymer molecular weight
US6812220B2 (en) * 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
JPWO2003023036A1 (ja) * 2001-09-05 2004-12-24 タカラバイオ株式会社 硫酸化フコガラクタン分解酵素遺伝子
AU2002348395A1 (en) 2001-10-23 2003-05-06 Waters Investments Limited System and method for determining radius of gyration, molecular weight, and intrinsic viscosity of a polymeric distribution using gel permeation chromatography and light-scattering detection
SE0200507D0 (sv) 2002-02-21 2002-02-21 Biovitrum Ab Chromatographic method
WO2004001031A1 (ja) 2002-06-20 2003-12-31 Takara Bio Inc. ナマコ由来硫酸化フカン分解酵素
US20040014179A1 (en) * 2002-06-20 2004-01-22 Novozymes A/S Flocculation with divalent salt
RU2247574C2 (ru) 2002-12-26 2005-03-10 Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН Средство, обладающее антикоагулянтным и иммунотропным действием
BRPI0418384A (pt) * 2003-05-30 2007-06-26 Arc Pharmaceuticals Inc composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
KR100695779B1 (ko) * 2004-09-20 2007-03-19 배태진 푸코이단을 생산하는 미생물 및 이를 이용한 푸코이단의생산 방법
WO2006032144A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
KR100623001B1 (ko) * 2004-10-11 2006-09-19 한국식품연구원 갈조류로 부터 항암 및 항고지혈 활성을 갖는 식품소재용 라미나란과 휴코이단의 일괄 분리 정제방법
CN1305885C (zh) * 2004-12-31 2007-03-21 中国科学院海洋研究所 海带中l－褐藻糖的制备方法
US20090105190A1 (en) * 2005-03-01 2009-04-23 Koji Hatano Method for Producing Fucoidan, Fucoidan, and Fucoidan-Containing Composition
US8426381B2 (en) 2005-09-09 2013-04-23 Lucas Meyer Cosmetics Canada Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
US8598337B2 (en) * 2006-01-13 2013-12-03 Baxter International Inc. Method for purifying polysaccharides
US7803629B2 (en) 2006-06-27 2010-09-28 Chevron Phillips Chemical Company, Lp Method for employing SEC-FTIR data to predict mechanical properties of polyethylene
CN1985846B (zh) 2006-09-04 2011-08-31 北京世纪博康医药科技有限公司 褐藻多糖硫酸酯在制备治疗心脑血管疾病的药物中的用途
CN1985847B (zh) * 2006-09-04 2011-10-05 北京世纪博康医药科技有限公司 低分子量褐藻多糖硫酸酯在制备治疗心脑血管疾病的药物中的用途
KR100705975B1 (ko) 2006-10-02 2007-04-10 이엔지바이오 주식회사 생체이용성 후코이단 및 그의 제조방법
CN101011411A (zh) 2006-12-08 2007-08-08 北京世纪博康医药科技有限公司 褐藻多糖硫酸酯在制备治疗肝脏疾病的药物中的用途
WO2008103324A1 (en) * 2007-02-19 2008-08-28 Wms Gaming Inc. Network diagnostics in a wagering game system
WO2008103234A1 (en) 2007-02-23 2008-08-28 Baxter, International Inc. Process methods for fucoidan purification from seaweed extracts
CN100540568C (zh) 2007-04-20 2009-09-16 中国科学院海洋研究所 一种提取褐藻多糖硫酸酯的方法
US7818109B2 (en) 2007-10-23 2010-10-19 Bose Corporation Methods and apparatus for securing an active vehicle seat
CN101156664B (zh) 2007-11-21 2010-08-11 上海理工大学 从海带提碘碱炼液中提取岩藻多糖的方法
CN101959868A (zh) 2008-02-28 2011-01-26 日本新药株式会社 纤维化抑制剂
WO2010110223A1 (ja) 2009-03-23 2010-09-30 国立大学法人鳥取大学 抗腫瘍作用を有するフコイダン
KR20100138440A (ko) * 2009-06-25 2010-12-31 주식회사 한립생명공학 푸코이단 분해 효소 및 이의 제조방법
JO3676B1 (ar) * 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
CN101659709B (zh) 2009-09-18 2011-09-07 集美大学 岩藻聚糖的制备方法
AU2011205271B2 (en) 2010-01-14 2014-01-30 Baxalta GmbH Methods and compositions for treating bleeding disorders
CN102821770A (zh) * 2010-02-22 2012-12-12 玛丽诺瓦股份有限公司 抗病毒制剂
PT2595722E (pt) 2010-07-22 2015-03-02 Heineken Supply Chain Bv Método para estabilização de bebidas fermentadas com levedura campo técnico da invenção
JP6363017B2 (ja) 2011-09-01 2018-07-25 中外製薬株式会社 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法
JP2013180994A (ja) 2012-03-02 2013-09-12 Kokando:Kk 単純ヘルペスウイルス２型感染予防剤およびインフルエンザウイルス感染治療剤
EP2838643B1 (en) 2012-04-20 2021-06-16 Vlaamse Instelling voor Technologisch Onderzoek (VITO) Improved dilute chemical reaction process with membrane separation step
KR20140033692A (ko) * 2012-09-10 2014-03-19 차의과학대학교 산학협력단 고분자량의 푸코이단을 포함하는 미백용 조성물
CN202778304U (zh) 2012-09-11 2013-03-13 湖南金能机械制造有限公司 一种循环泵分流搅拌装置
JP2014124579A (ja) 2012-12-26 2014-07-07 Sekisui Chem Co Ltd 有機排水の処理装置
JP6336487B2 (ja) 2013-01-25 2018-06-06 マリノヴァ プロプライエタリー リミテッド 処理方法
FR3020570B1 (fr) * 2014-04-30 2017-07-21 Pierre Fabre Dermo-Cosmetique Association d'un acide hyaluronique et d'un polysaccharide sulfate
KR101635268B1 (ko) * 2014-07-23 2016-06-30 제주대학교 산학협력단 후코이단을 함유하는 비장세포의 생존 및 기능 증진 효과를 가진 면역증강용 조성물
KR101531479B1 (ko) 2014-11-21 2015-06-26 세원셀론텍(주) 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법
CN105732834A (zh) * 2014-12-10 2016-07-06 黑龙江众生生物工程有限公司 一种褐藻岩藻聚糖硫酸酯提取纯化方法
CN104586878A (zh) 2015-01-14 2015-05-06 青岛海洋生物医药研究院股份有限公司 岩藻聚糖硫酸酯及低分子量岩藻聚糖硫酸酯在制备抗代谢综合症的药物和保健品中的应用
WO2016117024A1 (ja) 2015-01-20 2016-07-28 三菱化学エンジニアリング株式会社 酸素を含有するマイクロナノバブル及び殺菌性を有する気体を含有するマイクロナノバブルの供給装置を備えた生物反応装置
SG10201909456TA (en) 2015-04-24 2019-11-28 Univ Nanyang Tech Method and apparatus for assessing a state of fouling of a reverse osmosis system
WO2017042603A1 (en) 2015-09-07 2017-03-16 Total Sa Method for determining the weight-average molecular weight of a water-soluble high molecular weight polymer
CN105399848B (zh) 2015-11-20 2017-11-17 中国科学院上海药物研究所 一种岩藻聚糖硫酸酯、其制备方法和用途
CN106832022A (zh) 2015-12-04 2017-06-13 威海市宇王集团有限公司 一种提取岩藻聚糖硫酸酯的方法
CN106957374A (zh) * 2016-01-12 2017-07-18 中国科学院过程工程研究所 一种从藻类中提取褐藻糖胶和褐藻胶的方法
WO2017160739A1 (en) 2016-03-14 2017-09-21 Pendo TECH Processing system for multiple tangential flow filtration stations in bioprocessing applications
CN107382660A (zh) 2016-05-14 2017-11-24 江西理文化工有限公司 一种二氟一氯甲烷生产中气相除酸方法
US10139378B2 (en) 2016-05-16 2018-11-27 Exxonmobil Chemical Patents Inc. Methods of determining molecular weight and comonomer characteristics of a copolymer in polymer blends
KR101950246B1 (ko) 2017-02-14 2019-02-22 (주)필로스 비상용 이동식 막여과 정수 장치
CN107382666A (zh) * 2017-07-26 2017-11-24 中国水产科学研究院黄海水产研究所 一种海带漂烫水中可溶性有机物的节能高效提取方法
EP3829600A4 (en) 2018-07-27 2022-06-15 Arc Medical Devices, Inc. LOW ENDOTOXIN FUCCO COMPOSITIONS, SYSTEMS AND METHODS
CN112512667B (zh) 2019-03-05 2022-12-06 Arc医疗器械股份有限公司 用于粘性组合物的切向流过滤的系统和方法
JP7227346B2 (ja) 2019-03-05 2023-02-21 エーアールシー メディカル デバイス，インク． 生体ポリマー混合物の分子量分布を予測する方法

Also Published As

Publication number Publication date
WO2020019081A1 (en) 2020-01-30
CA3106464A1 (en) 2020-01-30
MX2021000863A (es) 2021-07-15
SG11202100390SA (en) 2021-02-25
WO2020019079A1 (en) 2020-01-30
JP7477238B2 (ja) 2024-05-01
PH12021550106A1 (en) 2021-10-04
US11938145B2 (en) 2024-03-26
PH12021550105A1 (en) 2021-10-04
US20210290658A1 (en) 2021-09-23
JP2022177066A (ja) 2022-11-30
AU2019312088A1 (en) 2021-02-04
CN112533989A (zh) 2021-03-19
US11446326B2 (en) 2022-09-20
AU2019310360B2 (en) 2021-10-28
BR112021000623A2 (pt) 2021-04-13
TW202019444A (zh) 2020-06-01
PH12021550103A1 (en) 2021-10-04
TW202007399A (zh) 2020-02-16
AU2019310194B2 (en) 2021-07-22
JP2022514723A (ja) 2022-02-15
AU2022200569A1 (en) 2022-02-17
ZA202100270B (en) 2022-08-31
JP2021532137A (ja) 2021-11-25
EP3830139A1 (en) 2021-06-09
IL280183A (en) 2021-03-01
IL280169A (en) 2021-03-01
PH12021550104A1 (en) 2021-10-04
CN112513104B (zh) 2023-06-13
JP2023085302A (ja) 2023-06-20
CA3106458A1 (en) 2020-01-30
US20210292441A1 (en) 2021-09-23
JP2023081932A (ja) 2023-06-13
JP7302831B2 (ja) 2023-07-04
KR20210040359A (ko) 2021-04-13
WO2020019078A1 (en) 2020-01-30
BR112021000617A2 (pt) 2021-04-06
AU2019310656A1 (en) 2021-02-04
IL280168A (en) 2021-03-01
JP2021531392A (ja) 2021-11-18
CA3106456A1 (en) 2020-01-30
SG11202100388TA (en) 2021-02-25
EP3830182A4 (en) 2022-06-29
KR20210040360A (ko) 2021-04-13
KR20210036913A (ko) 2021-04-05
CN112513103A (zh) 2021-03-16
CN112513103B (zh) 2023-04-25
TW202019443A (zh) 2020-06-01
JP2021533218A (ja) 2021-12-02
JP2022177065A (ja) 2022-11-30
CN112513165A (zh) 2021-03-16
IL280174A (en) 2021-03-01
US20210290660A1 (en) 2021-09-23
EP3829600A1 (en) 2021-06-09
WO2020019077A1 (en) 2020-01-30
US11642368B2 (en) 2023-05-09
BR112021000626A2 (pt) 2021-04-13
MX2021000860A (es) 2021-07-15
CN112513165B (zh) 2023-04-25
TW202020035A (zh) 2020-06-01
EP3829600A4 (en) 2022-06-15
AU2021254608A1 (en) 2021-11-18
EP3830139A4 (en) 2022-04-27
EP3830183A4 (en) 2022-06-08
EP3830138A1 (en) 2021-06-09
KR20210035172A (ko) 2021-03-31
AU2019311591A1 (en) 2021-02-04
US11628183B2 (en) 2023-04-18
WO2020019080A1 (en) 2020-01-30
AU2019310656B2 (en) 2022-03-10
AU2019310194A1 (en) 2021-02-04
AU2019311591B2 (en) 2021-11-04
SG11202100391VA (en) 2021-02-25
AU2019310360A1 (en) 2021-02-04
BR112021000631A2 (pt) 2021-04-06
AU2022200771A1 (en) 2022-02-24
CA3106465A1 (en) 2020-01-30
JP2022177054A (ja) 2022-11-30
AU2019312088B2 (en) 2021-11-18
MX2021000861A (es) 2021-03-26
EP3830182A1 (en) 2021-06-09
EP3830138A4 (en) 2023-02-08
ZA202100275B (en) 2022-08-31
US20210299159A1 (en) 2021-09-30
EP3830183A1 (en) 2021-06-09
IL280172A (en) 2021-03-01
SG11202100397UA (en) 2021-02-25
AU2022201112A1 (en) 2022-03-10
US20210290659A1 (en) 2021-09-23
ZA202100272B (en) 2022-08-31
CN112513104A (zh) 2021-03-16
AU2022203958A1 (en) 2022-06-23
US11419891B2 (en) 2022-08-23
JP2021531305A (ja) 2021-11-18
CA3106466A1 (en) 2020-01-30
SG11202100393TA (en) 2021-02-25
KR20210036914A (ko) 2021-04-05
CN112770763A (zh) 2021-05-07
BR112021000621A2 (pt) 2021-04-13
MX2021000864A (es) 2021-03-26
JP7272707B2 (ja) 2023-05-12

Similar Documents

Publication Publication Date Title
PH12021550106A1 (en) Highly purified fucans for the treatment of fibrous adhesions
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
SA517381996B1 (ar) تركيبة لتضميد الجرح
SA517381998B1 (ar) تركيبة لتضميد الجرح
MX2020013853A (es) Compuestos innovadores.
MX2016014623A (es) Composiciones de combustible.
MX2022001778A (es) Metodos para tratar esquizofrenia.
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
MX2019013419A (es) Compuestos plaguicidas biciclicos.
AU2020258568A8 (en) CD73 inhibitors
MX2021001613A (es) Anticuerpos anti-factor xi.
PH12021550329A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2021004387A (es) Composiciones y metodos para el tratamiento de sindrome vascular de ehlers danlos y trastornos asociados.
AU2020378127A8 (en) Compounds as CD73 inhibitors
PH12019501977A1 (en) Additive composition for ground improvement
MX2021002286A (es) Terapias de combinacion.
MX2021002294A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
MY194224A (en) Compounds and compositions useful as demulsifiers
AR115843A1 (es) Fucanos altamente purificados para el tratamiento de adherencias fibrosas y métodos para obtenerlos
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MX2022003816A (es) Compuestos antibacterianos.
WO2018137883A3 (de) Wirkverbesserte flammschutzzusammensetzungen enthaltend ein phosphonsäurederivat
MX2016010431A (es) Composiciones para la prevencion y/o el tratamiento de patologias relacionadas con alfa-glucosidasa.
MX2020009227A (es) Nuevas composiciones de poliisocianatos.